Main content

    Colorectal / Anal Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: InterAACT - An International Multicentre Open Label Randomized Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease
    Description: This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery
    Investigators: NCI - National Cancer Institute
    Eligibility: Male & female subjects, 18 y/o and older, with histological or cytological confirmation of epidermoid anal carcinoma (includes squamous, basaloid and cloacogenic lesions) from the primary tumor or a newly diagnosed recurrent/metastatic lesion inoperable. Locally recurrent or metastatic disease (tumor resectability should be assessed by a local surgeon or multidisciplinary team)
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study EA2133

    Title: A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer
    Description: This study is to examine if Nivolumab alone or in combination with Ipilimumab will demonstrate a meaningful objective response rate in patients with recurrent and metastatic colon cancer who also have a specific biomarker in their tumors
    Investigators: Ari Baron, MD
    Eligibility: Male & female subjects, 18 y/o and older, with histologically confirmed colorectal cancer
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study BMS CA209-142

    Title: A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision
    Description: The purpose of this study is to compare the effects of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX
    Investigators: NCI - National Cancer Institute
    Eligibility: Subjects, 18 years and older, who have a diagnosis of rectal adenocarcinoma and radiologically measurable or clinically evaluable disease as defined in the protocol
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study NCCTG N1048

    • updated September 2016

    Back to top